Problems in the management of opportunistic infections in patients infected with human immunodeficiency virus
- PMID: 2182728
- DOI: 10.1093/infdis/161.5.858
Problems in the management of opportunistic infections in patients infected with human immunodeficiency virus
Abstract
Opportunistic infections ultimately occur in most patients infected with human immunodeficiency virus (HIV) and are responsible for 90% of deaths. Over the decade since the acquired immunodeficiency syndrome (AIDS) was first recognized, important advances have been made in reducing the morbidity and mortality of opportunistic infections in patients infected with HIV. These include an improved understanding of the relationship between immunologic parameters and infection, allowing the occurrence of infectious complications to be more predictable; development of prophylactic regimens and chronic suppressive regimens that are effective, well tolerated, and convenient; and emphasis on earlier diagnosis and therapeutic intervention of those infectious processes that are not prevented. These advances have allowed the quality and duration of patient survival to improve during this decade, but they can also be anticipated to alter the spectrum of clinical manifestations that health care providers are going to see during this epidemic's second decade.
Similar articles
-
Human immunodeficiency virus (HIV)-associated pneumocystosis.Curr Clin Top Infect Dis. 1991;11:19-34. Curr Clin Top Infect Dis. 1991. PMID: 1867767 Review. No abstract available.
-
Pneumocystis pneumonia in HIV-1-infected patients.Respir Investig. 2019 May;57(3):213-219. doi: 10.1016/j.resinv.2019.01.009. Epub 2019 Feb 26. Respir Investig. 2019. PMID: 30824356 Review.
-
Pneumocystis carinii pneumonia (PCP).Prog Clin Parasitol. 1991;2:27-71. Prog Clin Parasitol. 1991. PMID: 1893119 Review. No abstract available.
-
Decisions in P. carinii pneumonia.Hosp Pract (Off Ed). 1990 Apr 30;25(4A):8, 13-4. Hosp Pract (Off Ed). 1990. PMID: 2109757 No abstract available.
-
[Antimicrobial therapy for patients with HIV infection].Nihon Naika Gakkai Zasshi. 2006 Nov 10;95(11):2214-9. doi: 10.2169/naika.95.2214. Nihon Naika Gakkai Zasshi. 2006. PMID: 17168395 Review. Japanese. No abstract available.
Cited by
-
Trimethoprim and other nonclassical antifolates an excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors.J Antibiot (Tokyo). 2020 Jan;73(1):5-27. doi: 10.1038/s41429-019-0240-6. Epub 2019 Oct 2. J Antibiot (Tokyo). 2020. PMID: 31578455 Free PMC article. Review.
-
Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-d]pyrimidine antifolates.J Med Chem. 2008 Sep 25;51(18):5789-97. doi: 10.1021/jm8006933. J Med Chem. 2008. PMID: 18800768 Free PMC article.
-
Structure-activity and structure-selectivity studies on diaminoquinazolines and other inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.Antimicrob Agents Chemother. 1995 Jan;39(1):79-86. doi: 10.1128/AAC.39.1.79. Antimicrob Agents Chemother. 1995. PMID: 7695334 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical